What is Betta Pharmaceuticals Co., Ltd.'s (300558.SZ) StockRank?

MoatMap's StockRank for Betta Pharmaceuticals Co., Ltd. (300558.SZ) is 46/100, with a Hold signal. This is a composite score combining Quality (53), Value (23), and Momentum (61) factor ranks across MoatMap's 19,000+ stock universe.

Does Betta Pharmaceuticals Co., Ltd. have an economic moat?

Betta Pharmaceuticals Co., Ltd. (300558.SZ) has a Quality factor score of 53/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Betta Pharmaceuticals Co., Ltd. a buy, hold, or sell?

MoatMap's current signal for Betta Pharmaceuticals Co., Ltd. (300558.SZ) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Betta Pharmaceuticals Co., Ltd. in?

Betta Pharmaceuticals Co., Ltd. (300558.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300558.SZ

HOLDREMOVE

Betta Pharmaceuticals Co., Ltd. · Healthcare · China · $3.3B · Avg Vol: $104M/d

StockRank

P/E (TTM)

50.6x

ROE

6.8%

D/E

0.4x

Dividend %

0.3%

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Betta Pharmaceuticals is a domestic Chinese oncology player facing intense centralized drug procurement (VBP) pricing pressure, destroying its pricing power.

COMPANY DESCRIPTION

Betta Pharmaceuticals Co., Ltd. is a leading oncology-focused biopharmaceutical company in China, specializing in the development and commercialization of innovative targeted small-molecule drugs. Its flagship product, Conmana (icotinib), was China's first self-developed targeted lung cancer therapy, establishing a strong clinical and commercial moat. The company maintains a robust R&D pipeline focused on precision oncology, positioning it as a premier player in China's innovative drug market.

FINANCIAL SUMMARY

Year	2022	2023	2024	2025	CAGR
Revenue	351M	363M	427M	533M	14.9%
EPS	0.05	0.12	0.14	0.11	27.8%
Shares	417M	418M	418M	421M	+0.8%
Debt	261M	359M	344M	355M	10.8%
Equity	717M	776M	824M	975M	10.8%
Op CF	45M	135M	135M	135M	43.8%
Inv CF	-196M	-222M	-148M	-137M	—
Fin CF	139M	90M	-28M	-4M	—

PRICE (1M)-3.5%

SMA 50SMA 200

$7.56

RSI (14)

53.2

52W High

$11.76

From 52W High

0.6%

SCORE BREAKDOWN

Quality

ROIC

5.7%58.9

ROE

6.8%62.2

GP/Assets

28.0%61.6

Op. Margin

28.5%90.7

FCF/Assets

-3.0%40.8

Piotroski

—55.8

Int. Cover

6.4x57.9

D/E Ratio

0.37x37.7

Current Ratio

0.99x9.8

Value

P/E (TTM)

50.6x20.1

EV/EBITDA

20.5x17.9

P/FCF

—N/A

P/B

3.3x36.5

P/S

6.0x36.0

Div Yield

0.3%7.3

Momentum

52W High %

64%47.4

RS 6M

0%77.1

SMA 50/200

0.93x42.4

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+60%58.5

Q Growth

136%88.8

FUNDAMENTALS

Market Cap

$3.3B

P/E (Forward)

31.6x

Gross Margin

79.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300558.SZ are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
300558.SZ	Betta Pharmaceuticals Co., Ltd.(you)	$3.3B	46	HOLD
300199.SZ	Hybio Pharmaceutical Co., Ltd.	$3.0B	48	HOLD
688131.SS	Shanghai Haoyuan Chemexpress Co., Ltd.	$2.3B	50	HOLD
000534.SZ	Wedge Industrial Co.,Ltd.	$2.5B	39	HOLD
300601.SZ	Shenzhen Kangtai Biological Products Co., Ltd.	$2.1B	51	HOLD
002317.SZ	Guangdong Zhongsheng Pharmaceutical Co., Ltd.	$3.0B	60	HOLD
002675.SZ	Yantai Dongcheng Pharmaceutical Group Co.,Ltd.	$1.6B	43	HOLD
300026.SZ	Tianjin Chase Sun Pharmaceutical Co.,Ltd	$1.4B	43	HOLD
603538.SS	Ningbo Menovo Pharmaceutical Co., Ltd.	$1.6B	51	HOLD
6887.HK	Sunshine Lake Pharma Co., Ltd.	$2.7B	30	SELL

Peer medians: ROE 4.7% · P/E 27.6x · Gross margin 53.0%

Betta Pharmaceuticals Co., Ltd. (300558.SZ) — Stock Score Summary

Betta Pharmaceuticals Co., Ltd. (300558.SZ) has a MoatMap StockRank of 46/100 based on Quality (53/100), Value (23/100), and Momentum (61/100) factor scores. The current signal is HOLD. Betta Pharmaceuticals is a domestic Chinese oncology player facing intense centralized drug procurement (VBP) pricing pressure, destroying its pricing power.

Key Financial Metrics

Price	$7.56
Market Cap	$3.3B
P/E (TTM)	50.55
P/E (Forward)	31.60
Price/Book	3.29
Return on Equity	6.8%
Return on Invested Capital	5.7%
Debt/Equity	37.32
Gross Margin	79.0%
Operating Margin	28.5%
Revenue Growth	13.3%
Dividend Yield	0.3%
Free Cash Flow	$-7M

Betta Pharmaceuticals Co., Ltd. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is Betta Pharmaceuticals Co., Ltd.’s (300558.SZ) StockRank?: MoatMap’s StockRank for Betta Pharmaceuticals Co., Ltd. (300558.SZ) is 46/100, with a Hold signal. It is a composite of Quality (53), Value (23), and Momentum (61) factor ranks across MoatMap’s 19,000+ stock universe.
Does Betta Pharmaceuticals Co., Ltd. have an economic moat?: Betta Pharmaceuticals Co., Ltd. (300558.SZ) has a Quality factor score of 53/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Betta Pharmaceuticals Co., Ltd. a buy, hold, or sell?: MoatMap’s current signal for Betta Pharmaceuticals Co., Ltd. (300558.SZ) is Hold, based on a StockRank of 46/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Betta Pharmaceuticals Co., Ltd. in?: Betta Pharmaceuticals Co., Ltd. (300558.SZ) operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry (China).